Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne (NASDAQ: TECH) has partnered with Lunaphore to create an automated spatial multiomics workflow aimed at enhancing research in disease analysis and therapeutic development. This collaboration integrates Bio-Techne's RNAscope™ technology with Lunaphore's seqIF™ system for simultaneous detection of protein and RNA biomarkers. The innovative solution promises flexibility in panel designs and is expected to streamline workflows for researchers focused on various diseases, including cancer and neurodegenerative disorders. With RNAscope™'s extensive catalog of over 45,000 probes and proven sensitivity, the partnership aims to significantly accelerate the discovery of novel diagnostics and therapeutics.

Bio-Techne Corporation (NASDAQ: TECH) announced its participation in the American Association for Cancer Research (AACR) annual meeting from April 14-19, 2023, in Orlando, Florida. The company will showcase its extensive portfolio of products aimed at advancing cancer research and facilitating cell and gene therapy development. Featured products include reagents, immunoassays, proteomic instruments, and spatial biology solutions. Several scientists from Bio-Techne will present posters on topics such as biomarkers, structural biology, and spatial biology. Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and employs about 3,000 people globally.

Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on May 3, 2023, at 8:00 a.m. CDT to discuss its third quarter 2023 financial results. Investors can dial in at 1-877-300-8521 for U.S. calls or 1-412-317-6026 for international calls, using Conference ID 10177426. A rebroadcast will be available for those unable to join live, from 11:00 a.m. CDT on May 3 to 11:00 p.m. CDT on June 3, 2023. Bio-Techne is a leader in developing purified proteins and reagent solutions, generating approximately $1.1 billion in net sales for fiscal 2022 and employing around 3,000 employees globally.

Bio-Techne Corporation (NASDAQ: TECH) has completed its $257 million investment in Wilson Wolf Manufacturing, acquiring a 20% ownership stake. This investment was initiated after Wilson Wolf met its EBITDA target of $55 million. Bio-Techne has the option to acquire the remaining stake for $1 billion upon Wilson Wolf achieving $226 million in revenue or $136 million in EBITDA by December 31, 2027. If the milestones are not met, Bio-Techne can acquire Wilson Wolf for approximately 4.4 times its trailing revenue. Wilson Wolf is recognized for its innovative cell production technology used in cell and gene therapy.

Bio-Techne Corporation (NASDAQ: TECH) announced its completion of participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year initiative involving 24 partners. The initiative, which began in January 2021, focused on developing cell and gene therapy-specific analytical technologies. Data was collected during experiments on T-cell expansion bioprocesses, resulting in a first-of-its-kind dataset. The Ella™ platform from Bio-Techne played a key role in the research, which is set to enhance facilities in the UK. Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022.

Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, Executive Vice President and CFO, will present at the Barclays Global Healthcare Conference on March 14, 2023, at 2:35 p.m. EDT. A live webcast can be accessed on Bio-Techne's Investor Relations website.

Bio-Techne is a leader in developing high-quality purified proteins and reagents, generating approximately $1.1 billion in net sales in fiscal 2022. The company's extensive portfolio supports biomedical research and diagnostics, enhancing drug discovery and clinical testing.

Bio-Techne Corporation (NASDAQ: TECH) announced an investment of $257 million in Wilson Wolf Manufacturing, resulting in a 20% ownership stake. This follows Wilson Wolf achieving a trailing 12-month EBITDA of $55 million. Bio-Techne can acquire the remaining ownership for $1 billion if Wilson Wolf hits a revenue milestone of $226 million or $136 million in EBITDA by December 31, 2027. Wilson Wolf specializes in innovative cell production technology crucial for Cell and Gene Therapy. The investment is poised to enhance Bio-Techne's capacity in CGT manufacturing and streamline processes in the sector.

Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 2:10 p.m. EST. Investors can access a live webcast of the presentation through the company's Investor Relations website.

Bio-Techne is a prominent developer of purified proteins and reagent solutions, including cytokines, antibodies, and diagnostic products. The company generated approximately $1.1 billion in net sales for fiscal 2022 and employs around 3,000 people globally.